{{Short description|Vaccine that uses a weakened form of the germ}}
{{use dmy dates |date=April 2023}}
An '''attenuated vaccine''' (or a live attenuated vaccine, LAV) is a [[vaccine]] created by reducing the [[virulence]] of a [[pathogen]], but still keeping it viable (or "live").<ref>{{Cite journal|last1=Badgett|first1=Marty R.|last2=Auer|first2=Alexandra|last3=Carmichael|first3=Leland E.|last4=Parrish|first4=Colin R.|last5=Bull|first5=James J.|date=October 2002|title=Evolutionary Dynamics of Viral Attenuation|journal=Journal of Virology|volume=76|issue=20|pages=10524–10529|doi=10.1128/JVI.76.20.10524-10529.2002|issn=0022-538X|pmid=12239331|pmc=136581}}</ref> Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent.<ref>{{Cite journal|last1=Pulendran|first1=Bali|last2=Ahmed|first2=Rafi|date=June 2011|title=Immunological mechanisms of vaccination|journal=Nature Immunology|volume=12|issue=6|pages=509–517|doi=10.1038/ni.2039|issn=1529-2908|pmc=3253344|pmid=21739679}}</ref> These vaccines contrast to those produced by "killing" the pathogen ([[inactivated vaccine]]).

Attenuated vaccines stimulate a strong and effective immune response that is long-lasting.<ref name=":132">{{Cite web|title=Vaccine Types {{!}} Vaccines|url=https://www.vaccines.gov/basics/types|access-date=2020-11-16|website=www.vaccines.gov}}</ref> In comparison to inactivated vaccines, attenuated vaccines produce a stronger and more durable immune response with a quick immunity onset.<ref name=":52">{{Cite journal|last1=Gil|first1=Carmen|last2=Latasa|first2=Cristina|last3=García-Ona|first3=Enrique|last4=Lázaro|first4=Isidro|last5=Labairu|first5=Javier|last6=Echeverz|first6=Maite|last7=Burgui|first7=Saioa|last8=García|first8=Begoña|last9=Lasa|first9=Iñigo|last10=Solano|first10=Cristina|date=2020|title=A DIVA vaccine strain lacking RpoS and the secondary messenger c-di-GMP for protection against salmonellosis in pigs|journal=Veterinary Research|volume=51|issue=1|page=3|doi=10.1186/s13567-019-0730-3|issn=0928-4249|pmc=6954585|pmid=31924274 |doi-access=free }}</ref><ref name=":62">{{Cite journal|last1=Tretyakova|first1=Irina|last2=Lukashevich|first2=Igor S.|last3=Glass|first3=Pamela|last4=Wang|first4=Eryu|last5=Weaver|first5=Scott|last6=Pushko|first6=Peter|date=2013-02-04|title=Novel Vaccine against Venezuelan Equine Encephalitis Combines Advantages of DNA Immunization and a Live Attenuated Vaccine|journal=Vaccine|volume=31|issue=7|pages=1019–1025|doi=10.1016/j.vaccine.2012.12.050|issn=0264-410X|pmc=3556218|pmid=23287629}}</ref><ref name=":72">{{Cite journal|last1=Zou|first1=Jing|last2=Xie|first2=Xuping|last3=Luo|first3=Huanle|last4=Shan|first4=Chao|last5=Muruato|first5=Antonio E.|last6=Weaver|first6=Scott C.|last7=Wang|first7=Tian|last8=Shi|first8=Pei-Yong|date=2018-09-07|title=A single-dose plasmid-launched live-attenuated Zika vaccine induces protective immunity|journal=eBioMedicine|volume=36|pages=92–102|doi=10.1016/j.ebiom.2018.08.056|issn=2352-3964|pmc=6197676|pmid=30201444}}</ref> They are generally avoided in patients with severe immunodeficiencies.<ref>{{Cite web |date=2023-09-19 |title=ACIP Altered Immunocompetence Guidelines for Immunizations {{!}} CDC |url=https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html |access-date=2023-09-26 |website=www.cdc.gov |language=en-us}}</ref> Attenuated vaccines function by encouraging the body to create [[Antibody|antibodies]] and [[Adaptive immune system|memory immune cells]] in response to the specific pathogen which the vaccine protects against.<ref name=":02" /> Common examples of live attenuated vaccines are [[Measles vaccine|measles]], [[Mumps vaccine|mumps]], [[Rubella vaccine|rubella]], [[Yellow fever vaccine|yellow fever]], and some [[Influenza vaccine|influenza]] vaccines.<ref name=":132"/>

==Development==

=== Attenuated viruses ===
Viruses may be attenuated using the principles of [[evolution]] via [[serial passage]] of the virus through a foreign [[host (biology)|host]] species, such as:<ref>{{Cite journal|last1=Jordan|first1=Ingo|last2=Sandig|first2=Volker|date=2014-04-11|title=Matrix and Backstage: Cellular Substrates for Viral Vaccines|journal=Viruses|volume=6|issue=4|pages=1672–1700|doi=10.3390/v6041672|issn=1999-4915|pmc=4014716|pmid=24732259|doi-access=free}}</ref><ref name=":0">{{Cite book|date=2015|editor-last=Nunnally|editor-first=Brian K.|editor2-last=Turula|editor2-first=Vincent E.|editor3-last=Sitrin|editor3-first=Robert D.|title=Vaccine Analysis: Strategies, Principles, and Control|url=https://link.springer.com/book/10.1007/978-3-662-45024-6|language=en-gb|doi=10.1007/978-3-662-45024-6|isbn=978-3-662-45023-9|s2cid=39542692}}</ref>
* [[Tissue culture]]
* Embryonated [[egg (biology)|eggs]] (often chicken)
* Live animals

The initial virus population is applied to a foreign host. Through natural [[genetic variability]] or induced [[mutation]], a small percentage of the viral particles should have the capacity to infect the new host.<ref name=":0" /><ref name=":2">{{Cite journal|last=Hanley|first=Kathryn A.|date=December 2011|title=The double-edged sword: How evolution can make or break a live-attenuated virus vaccine|journal=Evolution|volume=4|issue=4|pages=635–643|doi=10.1007/s12052-011-0365-y|issn=1936-6426|pmc=3314307|pmid=22468165}}</ref> These strains will continue to evolve within the new host and the virus will gradually lose its efficacy in the original host, due to lack of [[selection pressure]].<ref name=":0" /><ref name=":2" /> This process is known as "passage" in which the virus becomes so well adapted to the foreign host that it is no longer harmful to the subject that is to receive the vaccine.<ref name=":2" /> This makes it easier for the host immune system to eliminate the agent and create the immunological memory cells which will likely protect the patient if they are infected with a similar version of the virus in "the wild".<ref name=":2" />

Viruses may also be [[Reverse genetics#Vaccine synthesis|attenuated via reverse genetics]].<ref>{{Cite journal|last1=Nogales|first1=Aitor|last2=Martínez-Sobrido|first2=Luis|date=2016-12-22|title=Reverse Genetics Approaches for the Development of Influenza Vaccines|journal=International Journal of Molecular Sciences|volume=18|issue=1|page=20|doi=10.3390/ijms18010020|issn=1422-0067|pmc=5297655|pmid=28025504|doi-access=free}}</ref> Attenuation by genetics is also used in the production of [[oncolytic virus]]es.<ref>{{cite journal |vauthors= Gentry GA |title= Viral thymidine kinases and their relatives |journal= Pharmacology & Therapeutics |volume= 54 |issue= 3 |pages= 319–55 |year= 1992 |pmid= 1334563 |doi= 10.1016/0163-7258(92)90006-L}}</ref>

=== Attenuated bacteria ===
Bacteria is typically attenuated by passage, similar to the method used in viruses.<ref>{{cite web |title=Immunology and Vaccine-Preventable Diseases |url=https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/prinvac.pdf |website=CDC}}</ref> Gene knockout guided by reverse genetics is also used.<ref>{{cite journal |last1=Xiong |first1=Kun |last2=Zhu |first2=Chunyue |last3=Chen |first3=Zhijin |last4=Zheng |first4=Chunping |last5=Tan |first5=Yong |last6=Rao |first6=Xiancai |last7=Cong |first7=Yanguang |title=Vi Capsular Polysaccharide Produced by Recombinant Salmonella enterica Serovar Paratyphi A Confers Immunoprotection against Infection by Salmonella enterica Serovar Typhi |journal=Frontiers in Cellular and Infection Microbiology |date=24 April 2017 |volume=7 |pages=135 |doi=10.3389/fcimb.2017.00135|pmid=28484685 |pmc=5401900 |doi-access=free }}</ref>

== Administration ==
Attenuated vaccines can be administered in a variety of ways:
* Injections:
** Subcutaneous (e.g. [[MMR vaccine|measles, mumps and rubella vaccine]], [[varicella vaccine]], [[yellow fever vaccine]])<ref name=":8">{{Cite journal|last=Herzog|first=Christian|date=2014|title=Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature|url=http://www.tandfonline.com/doi/full/10.1586/14760584.2014.883285|journal=Expert Review of Vaccines|language=en|volume=13|issue=3|pages=399–415|doi=10.1586/14760584.2014.883285|pmid=24512188|s2cid=46577849|issn=1476-0584}}</ref>
** Intradermal (e.g. [[Tuberculosis vaccines|tuberculosis vaccine]], [[smallpox vaccine]])<ref name=":8" />
* Mucosal:
** Nasal (e.g. [[live attenuated influenza vaccine]])<ref>{{Cite journal|last1=Gasparini|first1=R.|last2=Amicizia|first2=D.|last3=Lai|first3=P. L.|last4=Panatto|first4=D.|date=2011|title=Live attenuated influenza vaccine--a review|url=https://pubmed.ncbi.nlm.nih.gov/22010534|journal=Journal of Preventive Medicine and Hygiene|volume=52|issue=3|pages=95–101|issn=1121-2233|pmid=22010534}}</ref><ref name=":8" />
** Oral (e.g. [[oral polio vaccine]], [[Recombinant DNA|recombinant]] live attenuated [[cholera vaccine]], [[Typhoid vaccine|oral typhoid vaccine]], [[Rotavirus vaccine|oral rotavirus vaccine]])<ref name=":8" /><ref name=":9">{{Cite book|last=Morrow, W. John W.|url=https://www.worldcat.org/oclc/795120561|title=Vaccinology : Principles and Practice.|date=2012|publisher=John Wiley & Sons|others=Sheikh, Nadeem A., Schmidt, Clint S., Davies, D. Huw.|isbn=978-1-118-34533-7|location=Hoboken|oclc=795120561}}</ref>

Oral vaccines or subcutaneous/intramuscular injection are for individuals older than 12 months. Live attenuated vaccines, with the exception of the rotavirus vaccine given at 6 weeks, is not indicated for infants younger than 9 months.<ref>{{Cite web |title=Your Child's Immunizations: Rotavirus Vaccine (RV) (for Parents) - Nemours KidsHealth |url=https://kidshealth.org/en/parents/rotavirus-vaccine.html |access-date=2022-09-15 |website=kidshealth.org}}</ref>

==Mechanism==
Vaccines function by encouraging the creation of cells, such as [[Cytotoxic T cell|CD8+]] and [[T helper cell|CD4+ T lymphocytes]], or molecules, such as [[Antibody|antibodies]], that are specific to the [[pathogen]].<ref name=":02">{{Cite book|url=https://www.worldcat.org/oclc/989157433|title=Plotkin's vaccines|others=Plotkin, Stanley A., 1932-, Orenstein, Walter A.,, Offit, Paul A.|year=2018|isbn=978-0-323-39302-7|edition=Seventh|location=Philadelphia, PA|oclc=989157433}}</ref> The cells and molecules can either prevent or reduce infection by killing infected cells or by producing [[interleukin]]s.<ref name=":02" /> The specific effectors evoked can be different based on the vaccine.<ref name=":02" /> Live attenuated vaccines tend to help with the production of CD8+ cytotoxic T lymphocytes and T-dependent antibody responses.<ref name=":02" /> A vaccine is only effective for as long as the body maintains a population of these cells.<ref name=":02" />

Attenuated vaccines are “weakened” version of pathogens (virus or bacteria). They are modified so that it cannot cause harm or disease in the body but are still able to activate the immune system.<ref>{{Cite web |last=Policy (OIDP) |first=Office of Infectious Disease and HIV/AIDS |date=2021-04-26 |title=Vaccine Types |url=https://www.hhs.gov/immunization/basics/types/index.html |access-date=2022-09-15 |website=HHS.gov |language=en}}</ref> This type of vaccine works by activating both the cellular and humoral immune responses of the adaptive immune system. When a person receives an oral or injection of the vaccine, B cells, which help make antibodies, are activated in two ways: T cell-dependent and T-cell independent.<ref name=":5">{{Cite book |last=Sompayrac |first=Lauren |url=https://www.worldcat.org/oclc/1083261548 |title=How the immune system works |date=2019 |isbn=978-1-119-54212-4 |edition=Sixth |location=Hoboken, NJ |oclc=1083261548}}</ref>

In T-cell dependent activation of B cells, B cells first recognize and present the antigen on MHCII receptors. T-cells can then recognize this presentation and bind to the B cell, resulting in clonal proliferation. This also helps IgM and plasma cells production as well as immunoglobulin switching. On the other hand, T-cell independent activation of B cells is due to non-protein antigens. This can lead to production of IgM antibodies. Being able to produce a B-cell response as well as memory killer T cells is a key feature of attenuated virus vaccines that help induce a potent immunity.<ref name=":5" />

== Safety ==
Live-attenuated vaccines are safe and stimulate a strong and effective immune response that is long-lasting.<ref name=":132"/> Given pathogens are attenuated, it is extremely rare for pathogens to revert to their pathogenic form and subsequently cause disease.<ref name=":142">{{Cite web|title=MODULE 2 – Live attenuated vaccines (LAV) - WHO Vaccine Safety Basics|url=https://vaccine-safety-training.org/live-attenuated-vaccines.html|access-date=2020-11-16|website=vaccine-safety-training.org}}</ref> Additionally, within the five WHO-recommended live attenuated vaccines (tuberculosis, oral polio, measles, rotavirus, and yellow fever), severe adverse reactions are extremely rare.<ref name=":142" />

Individuals with severely compromised immune systems (e.g., [[HIV|HIV-infection]], [[chemotherapy]], [[Immunosuppression|immunosuppressive therapy]], [[lymphoma]], [[leukemia]], [[combined immunodeficiencies]]) typically should not receive live-attenuated vaccines as they may not be able to produce an adequate and safe immune response.<ref name=":132"/><ref name=":142"/><ref name=":15">{{Citation|last1=Yadav|first1=Dinesh K.|title=Chapter 26 - Vaccines: Present Status and Applications|date=2014-01-01|url=http://www.sciencedirect.com/science/article/pii/B9780124160026000262|work=Animal Biotechnology|pages=491–508|editor-last=Verma|editor-first=Ashish S.|place=San Diego|publisher=Academic Press|language=en|doi=10.1016/b978-0-12-416002-6.00026-2|isbn=978-0-12-416002-6|access-date=2020-11-16|last2=Yadav|first2=Neelam|last3=Khurana|first3=Satyendra Mohan Paul|s2cid=83112999 |editor2-last=Singh|editor2-first=Anchal}}</ref><ref name=":3">{{Cite journal|last1=Sobh|first1=Ali|last2=Bonilla|first2=Francisco A.|date=Nov 2016|title=Vaccination in Primary Immunodeficiency Disorders|url=https://linkinghub.elsevier.com/retrieve/pii/S2213219816304081|journal=The Journal of Allergy and Clinical Immunology: In Practice|language=en|volume=4|issue=6|pages=1066–1075|doi=10.1016/j.jaip.2016.09.012|pmid=27836056}}</ref> Household contacts of immunodeficient individuals are still able to receive most attenuated vaccines since there is no increased risk of infection transmission, with the exception being the oral polio vaccine.<ref name=":3" />

As precaution, live-attenuated vaccines are not typically administered during [[Immunization during pregnancy|pregnancy]].<ref name=":142" /><ref name=":04">{{Citation|last1=Su|first1=John R.|title=Vaccine Safety|date=2019|url=https://linkinghub.elsevier.com/retrieve/pii/B978032355435000001X|work=Vaccinations|pages=1–24|publisher=Elsevier|language=en|doi=10.1016/b978-0-323-55435-0.00001-x|isbn=978-0-323-55435-0|access-date=2020-11-17|last2=Duffy|first2=Jonathan|last3=Shimabukuro|first3=Tom T.|s2cid=239378645}}</ref> This is due to the risk of transmission of virus between mother and fetus.<ref name=":04" /> In particular, the [[Varicella vaccine|varicella]] and [[yellow fever vaccine]]s have been shown to have adverse effects on fetuses and nursing babies.<ref name=":04" />

Some live attenuated vaccines have additional common, mild adverse effects due to their administration route.<ref name=":04" /> For example, the [[live attenuated influenza vaccine]] is given nasally and is associated with nasal congestion.<ref name=":04" />

Compared to [[inactivated vaccine]]s, live-attenuated vaccines are more prone to immunization errors as they must be kept under strict conditions during the [[cold chain]] and carefully prepared (e.g., during reconstitution).<ref name=":132"/><ref name=":142"/><ref name=":15" />

== History ==
The history of [[vaccine]] development started with the creation of the [[smallpox vaccine]] by [[Edward Jenner]] in the late 18th century.<ref name=":18">{{Cite journal|last=Plotkin|first=Stanley|date=2014-08-26|title=History of vaccination|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=111|issue=34|pages=12283–12287|doi=10.1073/pnas.1400472111|issn=1091-6490|pmc=4151719|pmid=25136134|bibcode=2014PNAS..11112283P|doi-access=free}}</ref> Jenner discovered that inoculating a human with an animal [[Poxviridae|pox virus]] would grant immunity against [[smallpox]], a disease considered to be one of the most devastating in human history.<ref>{{Cite journal|last=Eyler|first=John M.|date=October 2003|title=Smallpox in history: the birth, death, and impact of a dread disease|url=https://doi.org/10.1016/S0022-2143(03)00102-1|journal=Journal of Laboratory and Clinical Medicine|volume=142|issue=4|pages=216–220|doi=10.1016/s0022-2143(03)00102-1|pmid=14625526|issn=0022-2143}}</ref><ref>{{Citation|last1=Thèves|first1=Catherine|title=History of Smallpox and Its Spread in Human Populations|date=2016-09-15|url=http://www.asmscience.org/content/book/10.1128/9781555819170.chap16|work=Paleomicrobiology of Humans|pages=161–172|editor-last=Drancourt|publisher=American Society of Microbiology|language=en|doi=10.1128/microbiolspec.poh-0004-2014|isbn=978-1-55581-916-3|access-date=2020-11-14|last2=Crubézy|first2=Eric|last3=Biagini|first3=Philippe|volume=4|issue=4|pmid=27726788|editor2-last=Raoult}}</ref> Although the original [[smallpox vaccine]] is sometimes considered to be an attenuated vaccine due to its live nature, it was not strictly-speaking attenuated since it was not derived directly from smallpox. Instead, it was based on the related and milder [[cowpox]] disease.<ref name=":11">{{Citation|last1=Galinski|first1=Mark S.|title=Live Attenuated Viral Vaccines|date=2015|url=https://doi.org/10.1007/978-3-662-45024-6_1|work=Vaccine Analysis: Strategies, Principles, and Control|pages=1–44|editor-last=Nunnally|editor-first=Brian K.|place=Berlin, Heidelberg|publisher=Springer|language=en|doi=10.1007/978-3-662-45024-6_1|isbn=978-3-662-45024-6|access-date=2020-11-14|last2=Sra|first2=Kuldip|last3=Haynes|first3=John I.|last4=Naspinski|first4=Jennifer|editor2-last=Turula|editor2-first=Vincent E.|editor3-last=Sitrin|editor3-first=Robert D.}}</ref><ref>{{Cite journal|date=2015-05-01|title=Live attenuated vaccines: Historical successes and current challenges|journal=Virology|language=en|volume=479-480|pages=379–392|doi=10.1016/j.virol.2015.03.032|issn=0042-6822|last1=Minor|first1=Philip D.|pmid=25864107|doi-access=free}}</ref> The discovery that diseases could be artificially attenuated came in the late 19th century when [[Louis Pasteur]] was able to derive an attenuated strain of [[chicken cholera]].<ref name=":11" /> Pasteur applied this knowledge to develop an attenuated [[Anthrax vaccines|anthrax vaccine]] and demonstrating its effectiveness in a public experiment.<ref name=":12">{{Cite journal|last=Schwartz|first=M.|date=7 July 2008|title=The life and works of Louis Pasteur|journal=Journal of Applied Microbiology|volume=91|issue=4|pages=597–601|doi=10.1046/j.1365-2672.2001.01495.x|issn=1364-5072|pmid=11576293|s2cid=39020116|doi-access=free}}</ref> The first [[rabies vaccine]] was subsequently produced by Pasteur and [[Pierre Paul Émile Roux|Emile Roux]] by growing the virus in rabbits and drying the affected nervous tissue.<ref name=":12" />

The technique of cultivating a virus repeatedly in artificial media and isolating less [[Virulence|virulent]] strains was pioneered in the early 20th century by [[Albert Calmette]] and [[Camille Guérin]] who developed an attenuated [[Tuberculosis vaccines|tuberculosis vaccine]] called the [[BCG vaccine]].<ref name=":18" /> This technique was later used by several teams when developing the vaccine for [[Yellow fever vaccine|yellow fever]], first by Sellards and [[Jean Laigret|Laigret]], and then by [[Max Theiler|Theiler]] and Smith.<ref name=":18" /><ref name=":11" /><ref name=":19">{{Cite journal|last=Frierson|first=J. Gordon|date=June 2010|title=The Yellow Fever Vaccine: A History|journal=The Yale Journal of Biology and Medicine|volume=83|issue=2|pages=77–85|issn=0044-0086|pmc=2892770|pmid=20589188}}</ref> The vaccine developed by Theiler and Smith proved to be hugely successful and helped establish recommended practices and regulations for many other vaccines. These include the growth of viruses in primary tissue culture (e.g., chick embryos), as opposed to animals, and the use of the seed stock system which uses the original attenuated viruses as opposed to derived viruses (done to reduce variance in vaccine development and decrease the chance of adverse effects).<ref name=":11" /><ref name=":19" /> The middle of the 20th century saw the work of many prominent virologists including [[Albert Sabin|Sabin]], [[Maurice Hilleman|Hilleman]], and [[John Franklin Enders|Enders]], and the introduction of several successful attenuated vaccines, such as those against [[Polio vaccine|polio]], [[Measles vaccine|measles]], [[Mumps vaccine|mumps]], and [[Rubella vaccine|rubella]].<ref>{{Cite journal|last1=Shampo|first1=Marc A.|last2=Kyle|first2=Robert A.|last3=Steensma|first3=David P.|date=July 2011|title=Albert Sabin—Conqueror of Poliomyelitis|journal=Mayo Clinic Proceedings|volume=86|issue=7|pages=e44|doi=10.4065/mcp.2011.0345|issn=0025-6196|pmc=3127575|pmid=21719614}}</ref><ref>{{Cite journal|last=Newman|first=Laura|date=2005-04-30|title=Maurice Hilleman|journal=BMJ: British Medical Journal|volume=330|issue=7498|pages=1028|doi=10.1136/bmj.330.7498.1028|pmc=557162|issn=0959-8138}}</ref><ref>{{Cite book|last=Katz|first=S. L.|title=Measles |chapter=John F. Enders and Measles Virus Vaccine—a Reminiscence |series=Current Topics in Microbiology and Immunology |date=2009|chapter-url=https://pubmed.ncbi.nlm.nih.gov/19198559/|volume=329|pages=3–11|doi=10.1007/978-3-540-70523-9_1|issn=0070-217X|pmid=19198559|isbn=978-3-540-70522-2|s2cid=2884917 }}</ref><ref>{{Cite journal|last=Plotkin|first=Stanley A.|date=2006-11-01|title=The History of Rubella and Rubella Vaccination Leading to Elimination|journal=Clinical Infectious Diseases|language=en|volume=43|issue=Supplement_3|pages=S164–S168|doi=10.1086/505950|pmid=16998777|issn=1058-4838|doi-access=free}}</ref>

==Advantages and disadvantages==

=== Advantages ===
* Accurately imitate natural infections.<ref name=":4">{{Citation|last1=Yadav|first1=Dinesh K.|title=Vaccines|date=2014|url=https://linkinghub.elsevier.com/retrieve/pii/B9780124160026000262|work=Animal Biotechnology|pages=491–508|publisher=Elsevier|language=en|doi=10.1016/b978-0-12-416002-6.00026-2|isbn=978-0-12-416002-6|access-date=2020-11-09|last2=Yadav|first2=Neelam|last3=Khurana|first3=Satyendra Mohan Paul|s2cid=83112999 }}</ref><ref name=":03">{{Cite journal|last1=Vetter|first1=Volker|last2=Denizer|first2=Gülhan|last3=Friedland|first3=Leonard R.|last4=Krishnan|first4=Jyothsna|last5=Shapiro|first5=Marla|date=2018-02-17|title=Understanding modern-day vaccines: what you need to know|journal=Annals of Medicine|volume=50|issue=2|pages=110–120|doi=10.1080/07853890.2017.1407035|issn=0785-3890|pmid=29172780|s2cid=25514266|doi-access=free}}</ref>
* Are effective at evoking both strong [[antibody]] and [[Cell-mediated immunity|cell-mediated]] immune reactions.<ref name=":4" /><ref name=":03" /><ref name=":52"/>
* Can elicit long-lasting or life-long immunity.<ref name=":4" /><ref name=":03" /><ref name=":62"/>
* Often only one or two doses are required.<ref name=":4" /><ref name=":03" /><ref name=":72"/>
* Quick immunity onset.<ref name=":52"/><ref name=":62"/><ref name=":72"/>
* Cost-effective (compared to some other health interventions).<ref>{{Cite journal|last=Minor|first=Philip D.|date=May 2015|title=Live attenuated vaccines: Historical successes and current challenges|journal=Virology|volume=479-480|pages=379–392|doi=10.1016/j.virol.2015.03.032|issn=1096-0341|pmid=25864107|doi-access=free}}</ref><ref>{{Citation|last1=Mak|first1=Tak W.|title=23 - Vaccines and Clinical Immunization|date=2006-01-01|url=http://www.sciencedirect.com/science/article/pii/B9780120884513500259|work=The Immune Response|pages=695–749|editor-last=Mak|editor-first=Tak W.|place=Burlington|publisher=Academic Press|language=en|isbn=978-0-12-088451-3|access-date=2020-11-14|last2=Saunders|first2=Mary E.|editor2-last=Saunders|editor2-first=Mary E.}}</ref>
* Can have strong beneficial [[Non-specific effect of vaccines|non-specific effects]].<ref name="Benn132">{{Cite journal|last1=Benn|first1=Christine S.|last2=Netea|first2=Mihai G.|last3=Selin|first3=Liisa K.|last4=Aaby|first4=Peter|date=September 2013|title=A small jab – a big effect: nonspecific immunomodulation by vaccines|journal=[[Trends in Immunology]]|volume=34|issue=9|pages=431–439|doi=10.1016/j.it.2013.04.004|pmid=23680130}}</ref>

=== Disadvantages ===
* In rare cases, particularly when there is inadequate vaccination of the population, natural [[mutation]]s during [[viral replication]], or interference by related viruses, can cause an attenuated virus to revert to its [[Wild type|wild-type]] form or mutate to a new [[Strain (biology)|strain]], potentially resulting in the new virus being infectious or pathogenic.<ref name=":4" /><ref name="Shimizu_20042">{{cite journal|display-authors=etal|vauthors=Shimizu H, Thorley B, Paladin FJ|date=December 2004|title=Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001|journal=J. Virol.|volume=78|issue=24|pages=13512–21|doi=10.1128/JVI.78.24.13512-13521.2004|pmc=533948|pmid=15564462}}</ref>
* Often not recommended for severely [[Immunodeficiency|immunocompromised]] patients due to the risk of potential complications.<ref name=":4" /><ref name="MMWR20112">{{cite news|last=Kroger|first=Andrew T.|author2=Ciro V. Sumaya|author3=Larry K. Pickering|author4=William L. Atkinson|date=2011-01-28|title=General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)|work=Morbidity and Mortality Weekly Report (MMWR)|publisher=[[Centers for Disease Control and Prevention]]|url=https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm?s_cid=rr6002a1_e|access-date=2011-03-11}}</ref><ref>{{Cite journal|last1=Cheuk|first1=Daniel KL|last2=Chiang|first2=Alan KS|last3=Lee|first3=Tsz Leung|last4=Chan|first4=Godfrey CF|last5=Ha|first5=Shau Yin|date=2011-03-16|title=Vaccines for prophylaxis of viral infections in patients with hematological malignancies|url=https://doi.org//10.1002/14651858.CD006505.pub2|journal=Cochrane Database of Systematic Reviews|issue=3|pages=CD006505|doi=10.1002/14651858.cd006505.pub2|pmid=21412895|issn=1465-1858}}</ref>
* Live strains typically require advanced maintenance, such as refrigeration and fresh media, making transport to remote areas difficult and costly.<ref name=":4" /><ref>{{Cite journal|last=Levine|first=Myron M.|date=2011-12-30|title="IDEAL" vaccines for resource poor settings|url=http://www.sciencedirect.com/science/article/pii/S0264410X1101886X|journal=Vaccine|series=Smallpox Eradication after 30 Years: Lessons, Legacies and Innovations|language=en|volume=29|pages=D116–D125|doi=10.1016/j.vaccine.2011.11.090|pmid=22486974|issn=0264-410X}}</ref>

== List of attenuated vaccines ==

=== Currently in-use ===

For many of the pathogens listed below there are many vaccines, the list below simply indicates that there are one (or more) attenuated vaccines for that particular pathogen, not that all vaccines for that pathogen are attenuated.{{cn|date=May 2023}}

==== Bacterial vaccines ====
* [[Anthrax vaccines|Anthrax vaccine]]<ref>{{Cite journal|last1=Donegan|first1=Sarah|last2=Bellamy|first2=Richard|last3=Gamble|first3=Carrol L|date=2009-04-15|title=Vaccines for preventing anthrax|url= |journal=Cochrane Database of Systematic Reviews|volume=2009 |issue=2|pages=CD006403|doi=10.1002/14651858.cd006403.pub2|issn=1465-1858|pmc=6532564|pmid=19370633}}</ref>
* [[Cholera vaccine]]<ref>{{Cite journal|last=Harris|first=Jason B|date=2018-11-15|title=Cholera: Immunity and Prospects in Vaccine Development|journal=The Journal of Infectious Diseases|volume=218|issue=Suppl 3|pages=S141–S146|doi=10.1093/infdis/jiy414|issn=0022-1899|pmc=6188552|pmid=30184117}}</ref>
* [[Plague vaccine]]<ref>{{Cite journal|last1=Verma|first1=Shailendra Kumar|last2=Tuteja|first2=Urmil|date=2016-12-14|title=Plague Vaccine Development: Current Research and Future Trends|journal=Frontiers in Immunology|volume=7|page=602|doi=10.3389/fimmu.2016.00602|issn=1664-3224|pmc=5155008|pmid=28018363|doi-access=free}}</ref>
* [[Salmonella]] vaccine<ref>{{Cite journal|last1=Odey|first1=Friday|last2=Okomo|first2=Uduak|last3=Oyo-Ita|first3=Angela|date=2018-12-05|title=Vaccines for preventing invasive salmonella infections in people with sickle cell disease|url= |journal=Cochrane Database of Systematic Reviews|volume=12|issue=4|pages=CD006975|doi=10.1002/14651858.cd006975.pub4|issn=1465-1858|pmc=6517230|pmid=30521695}}</ref>
* [[Tuberculosis vaccines|Tuberculosis vaccine]]<ref>{{Cite journal|last1=Schrager|first1=Lewis K.|last2=Harris|first2=Rebecca C.|last3=Vekemans|first3=Johan|date=2019-02-24|title=Research and development of new tuberculosis vaccines: a review|journal=F1000Research|volume=7|page=1732|doi=10.12688/f1000research.16521.2|issn=2046-1402|pmc=6305224|pmid=30613395 |doi-access=free }}</ref>
* [[Typhoid vaccine]]<ref>{{Cite journal|last1=Meiring|first1=James E|last2=Giubilini|first2=Alberto|last3=Savulescu|first3=Julian|last4=Pitzer|first4=Virginia E|last5=Pollard|first5=Andrew J|date=2019-11-01|title=Generating the Evidence for Typhoid Vaccine Introduction: Considerations for Global Disease Burden Estimates and Vaccine Testing Through Human Challenge|journal=Clinical Infectious Diseases|volume=69|issue=Suppl 5|pages=S402–S407|doi=10.1093/cid/ciz630|issn=1058-4838|pmc=6792111|pmid=31612941}}</ref>

==== Viral vaccines ====
* [[Live attenuated influenza vaccine|Live attenuated influenza vaccine (LAIV)]]<ref>{{Cite journal|last1=Jefferson|first1=Tom|last2=Rivetti|first2=Alessandro|last3=Di Pietrantonj|first3=Carlo|last4=Demicheli|first4=Vittorio|date=2018-02-01|title=Vaccines for preventing influenza in healthy children|url= |journal=Cochrane Database of Systematic Reviews|volume=2018|issue=2 |pages=CD004879|doi=10.1002/14651858.cd004879.pub5|issn=1465-1858|pmc=6491174|pmid=29388195}}</ref>
* [[Japanese encephalitis vaccine]]<ref>{{Cite journal|last1=Yun|first1=Sang-Im|last2=Lee|first2=Young-Min|date=2014-02-01|title=Japanese encephalitis|journal=Human Vaccines & Immunotherapeutics|volume=10|issue=2|pages=263–279|doi=10.4161/hv.26902|issn=2164-5515|pmc=4185882|pmid=24161909}}</ref>
* [[Measles vaccine]]<ref>{{Cite journal|last=Griffin|first=Diane E.|date=2018-03-01|title=Measles Vaccine|journal=Viral Immunology|volume=31|issue=2|pages=86–95|doi=10.1089/vim.2017.0143|issn=0882-8245|pmc=5863094|pmid=29256824}}</ref>
* [[Mumps vaccine]]<ref>{{Cite journal|last1=Su|first1=Shih-Bin|last2=Chang|first2=Hsiao-Liang|last3=Chen|first3=And Kow-Tong|date=5 March 2020|title=Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine|journal=International Journal of Environmental Research and Public Health|volume=17|issue=5|page=1686|doi=10.3390/ijerph17051686|issn=1660-4601|pmc=7084951|pmid=32150969|doi-access=free}}</ref>
* [[MR vaccine|Measles and rubella (MR) vaccine]]<ref>{{Cite journal|date=May 2014|title=Observed Rate of Vaccine Reactions – Measles, Mumps and Rubella Vaccines|url=https://www.who.int/vaccine_safety/initiative/tools/MMR_vaccine_rates_information_sheet.pdf|journal=World Health Organization Information Sheet}}</ref>
* [[MMR vaccine|Measles, mumps, and rubella (MMR) vaccine]]<ref name=":1">{{Cite journal|last1=Di Pietrantonj|first1=Carlo|last2=Rivetti|first2=Alessandro|last3=Marchione|first3=Pasquale|last4=Debalini|first4=Maria Grazia|last5=Demicheli|first5=Vittorio|date=April 20, 2020|title=Vaccines for measles, mumps, rubella, and varicella in children|journal=The Cochrane Database of Systematic Reviews|volume=4|issue=4 |pages=CD004407|doi=10.1002/14651858.CD004407.pub4|issn=1469-493X|pmc=7169657|pmid=32309885}}</ref>
* [[MMRV vaccine|Measles, mumps, rubella and varicella (MMRV) vaccine]]<ref name=":1" />
* [[Polio vaccine]]<ref>{{Cite journal|last1=Bandyopadhyay|first1=Ananda S.|last2=Garon|first2=Julie|last3=Seib|first3=Katherine|last4=Orenstein|first4=Walter A.|date=2015|title=Polio vaccination: past, present and future|journal=Future Microbiology|volume=10|issue=5|pages=791–808|doi=10.2217/fmb.15.19|issn=1746-0921|pmid=25824845|doi-access=free}}</ref>
* [[Rotavirus vaccine]]<ref>{{Cite journal|last1=Bruijning-Verhagen|first1=Patricia|last2=Groome|first2=Michelle|date=July 2017|title=Rotavirus Vaccine: Current Use and Future Considerations|url=https://pubmed.ncbi.nlm.nih.gov/28383393|journal=The Pediatric Infectious Disease Journal|volume=36|issue=7|pages=676–678|doi=10.1097/INF.0000000000001594|issn=1532-0987|pmid=28383393|s2cid=41278475}}</ref>
* [[Rubella vaccine]]<ref>{{Cite journal|last1=Lambert|first1=Nathaniel|last2=Strebel|first2=Peter|last3=Orenstein|first3=Walter|last4=Icenogle|first4=Joseph|last5=Poland|first5=Gregory A.|date=2015-06-06|title=Rubella|journal=Lancet|volume=385|issue=9984|pages=2297–2307|doi=10.1016/S0140-6736(14)60539-0|issn=0140-6736|pmc=4514442|pmid=25576992}}</ref>
* [[Smallpox vaccine]]<ref>{{Cite journal|last1=Voigt|first1=Emily A.|last2=Kennedy|first2=Richard B.|last3=Poland|first3=Gregory A.|date=September 2016|title=Defending against smallpox: a focus on vaccines|journal=Expert Review of Vaccines|volume=15|issue=9|pages=1197–1211|doi=10.1080/14760584.2016.1175305|issn=1744-8395|pmc=5003177|pmid=27049653}}</ref>
* [[Varicella vaccine]]<ref>{{Cite journal|last1=Marin|first1=Mona|last2=Marti|first2=Melanie|last3=Kambhampati|first3=Anita|last4=Jeram|first4=Stanley M.|last5=Seward|first5=Jane F.|date=March 1, 2016|title=Global Varicella Vaccine Effectiveness: A Meta-analysis|journal=Pediatrics|volume=137|issue=3|pages=e20153741|doi=10.1542/peds.2015-3741|issn=1098-4275|pmid=26908671|s2cid=25263970|doi-access=free}}</ref>
* [[Yellow fever vaccine]]<ref>{{Cite journal|last1=Monath|first1=Thomas P.|last2=Vasconcelos|first2=Pedro F. C.|date=March 2015|title=Yellow fever|url=https://pubmed.ncbi.nlm.nih.gov/25453327|journal=Journal of Clinical Virology|volume=64|pages=160–173|doi=10.1016/j.jcv.2014.08.030|issn=1873-5967|pmid=25453327|s2cid=5124080 }}</ref>
* [[Zoster vaccine|Zoster/shingles vaccine]]<ref>{{Cite journal|last=Schmader|first=Kenneth|date=August 7, 2018|title=Herpes Zoster|url=https://pubmed.ncbi.nlm.nih.gov/30083718/|journal=Annals of Internal Medicine|volume=169|issue=3|pages=ITC19–ITC31|doi=10.7326/AITC201808070|issn=1539-3704|pmid=30083718|s2cid=51926613}}</ref>

=== In development ===

==== Bacterial vaccines ====
* [[Enterotoxigenic Escherichia coli]] vaccine<ref>{{Cite journal|last1=Mirhoseini|first1=Ali|last2=Amani|first2=Jafar|last3=Nazarian|first3=Shahram|date=April 2018|title=Review on pathogenicity mechanism of enterotoxigenic Escherichia coli and vaccines against it|url=https://pubmed.ncbi.nlm.nih.gov/29474827/|journal=Microbial Pathogenesis|volume=117|pages=162–169|doi=10.1016/j.micpath.2018.02.032|issn=1096-1208|pmid=29474827}}</ref>

==== Viral vaccines ====
* [[Tick-borne encephalitis vaccine]]<ref>{{Cite journal|last1=Kubinski|first1=Mareike|last2=Beicht|first2=Jana|last3=Gerlach|first3=Thomas|last4=Volz|first4=Asisa|last5=Sutter|first5=Gerd|last6=Rimmelzwaan|first6=Guus F.|date=2020-08-12|title=Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise|journal=Vaccines|volume=8|issue=3|page=451|doi=10.3390/vaccines8030451|issn=2076-393X|pmc=7564546|pmid=32806696|doi-access=free}}</ref>
* [[COVID-19]]<ref>{{cite web |title=Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04619628 |website=ClinicalTrials.gov |publisher=United States National Library of Medicine |access-date=8 June 2021}}</ref>

==References==

{{Reflist}}
{{Scholia}}

==External links==
* [https://web.archive.org/web/20070604164605/http://www.polioeradication.org/vaccines.asp Global Polio Eradication Initiative: Advantages and Disadvantages of Vaccine Types]
* [https://www.cdc.gov/h1n1flu/vaccination/nasalspray_qa.htm CDC H1N1 Flu / 2009 H1N1 Nasal Spray Vaccine Q&A] at the website of the US [[Centers for Disease Control and Prevention]]

{{Portal bar|Medicine|Viruses}}
{{Vaccines}}
{{Authority control}}

[[Category:Vaccination]]
[[Category:Virology]]
[[Category:Live vaccines| ]]